Sorrento Therapeutics, Inc. Form SC 13D/A May 11, 2016 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

SCHEDULE 13D (Rule 13d-101)

(Amendment No. 3)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a)

Sorrento Therapeutics, Inc. (Name of Issuer)

Common Stock, par value \$0.0001 per share (Title of Class of Securities)

83587F202 (CUSIP Number)

Leonard A. Potter

President and Managing Member

Wildcat Capital Management, LLC

888 Seventh Avenue

New York, NY 10106

(212) 468-5100 (Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

May 10, 2016

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

(Continued on following pages)

(Page 1 of 15 Pages)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (<u>"Act</u>") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the *Notes*).

CUSIP No. 83587F202 13D Page 2 of 15 Pages

NAMES OF REPORTING PERSONS

1 ^r

Wildcat Capital Management, LLC CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

2

(see instructions)

(a)

(b) 3 SEC USE ONLY SOURCE OF FUNDS (see instructions)

4

OO (See Item 3) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED

PURSUANT TO ITEM 2(d) or 2(e) CITIZENSHIP OR PLACE OF ORGANIZATION

SOLE

6

5

Delaware

	7	VOTING POWER
		-0- SHARED
NUMBER OF SHARES		VOTING POWER
SHAKES	8	POWER
BENEFICIALLY		2,676,193 (See
OWNED BY		Items 3, 4 and
EACH REPORTING		5)
PERSON WITH	9	SOLE DISPOSITIVE POWER

Edgar Filing: Sorrento	Therapeutics, Ir	nc Form SC 13D/A
------------------------	------------------	------------------

	Eugar Filling. Soffenito Therapeutics, inc Form SO TSD/A
	-0- 10 SHARED DISPOSITIVE POWER
	2,676,193 (See Items 3, 4 and 5)
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	2,676,193 (See Items 3, 4 and 5)
	CHECK BOX IF THE
	AGGREGATE AMOUNT IN
12	ROW (11) EXCLUDES CERTAIN
	SHARES (see instructions) PERCENT OF CLASS REPRESENTED BY
13	AMOUNT IN ROW 11
14	6.7% (See Item 5)* TYPE OF REPORTING PERSON
	00

The calculation assumes that there are a total of 40,212,795 shares of Common Stock (as defined herein) outstanding * as of May 3, 2016, as set forth in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the Securities and Exchange Commission (the <u>"SEC</u>") on May 10, 2016.

CUSIP No. 83587F202 13D Page 3 of 15 Pages

NAMES OF REPORTING PERSONS

1

Wildcat – Liquid Alpha, LLC CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

2

(see instructions)

(a)

(b) 3 SEC USE ONLY SOURCE OF FUNDS (see instructions)

4

WC (See Item 3) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED

PURSUANT TO ITEM 2(d) or 2(e) CITIZENSHIP OR PLACE OF ORGANIZATION

SOLE

6

5

Delaware

	7	VOTING POWER
		-0- Shared
NUMBER OF SHARES		VOTING POWER
	8	
BENEFICIALLY		184,000 (See
OWNED BY		Items 3, 4 and
EACH REPORTING		5)
PERSON WITH	9	SOLE DISPOSITIVE POWER

Edgar Filing: Sorrento	Thoropoution	Ino Eorm	
Lugar i ning. Somenio	merapeutics,	IIIC I UIII	130 13D/A

	Edgar Filing: Sorrento Therapeutics, Inc Form SC 13D/A
	-0- 10 SHARED DISPOSITIVE POWER
	184,000 (See Items 3, 4 and 5)
	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
11	PERSON
	184,000 (See Items 3, 4 and 5) CHECK BOX IF THE AGGREGATE
12	AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) PERCENT OF CLASS REPRESENTED BY
13	AMOUNT IN ROW 11
14	0.5% (See Item 5)* TYPE OF REPORTING PERSON
	00

The calculation assumes that there are a total of 40,212,795 shares of Common Stock outstanding as of May 3, 2016, *as set forth in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the SEC on May 10, 2016.

CUSIP No. 83587F202 13D Page 4 of 15 Pages

NAMES OF REPORTING PERSONS

1

Infinity Q Capital Management, LLC CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

2 (see instructions)

(a)

(b) 3 SEC USE ONLY SOURCE OF FUNDS (see instructions)

4 Instructions

OO (See Item 3) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

- CITIZENSHIP OR PLACE OF ORGANIZATION
- 6

5

Delaware

	SOLE
	VOTING
7	POWER

		-0-
		SHARED
NUMBER OF		VOTING
SHARES		POWER
	8	
BENEFICIALLY		123,597 (See
OWNED BY		Items 3, 4 and
EACH REPORTING		5)

Edgar Filing: Sorrento Therapeutics, Inc. - Form SC 13D/A

PERSON WITH

- DISPOSITIVE
- 9 POWER

SOLE

-0-

10 SHARED DISPOSITIVE POWER

> 123,597 (See Items 3, 4 and 5)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING

11 PERSON

12

13

14

123,597 (See Items 3, 4 and 5) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN

- SHARES (see instructions)
- PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

0.3% (See Item 5)* TYPE OF REPORTING PERSON

00

The calculation assumes that there are a total of 40,212,795 shares of Common Stock outstanding as of May 3, 2016, * as set forth in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the SEC on May 10, 2016.

CUSIP No. 83587F202 13D Page 5 of 15 Pages

NAMES OF REPORTING PERSONS

1

Infinity Q Management Equity, LLC CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

2

(see instructions)

(a)

(b) 3 SEC USE ONLY SOURCE OF FUNDS (see instructions)

4 Instructions

OO (See Item 3) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

- CITIZENSHIP OR PLACE OF ORGANIZATION
- 6

5

Delaware

	SOLE
	VOTING
7	POWER

		-0-
		SHARED
NUMBER OF		VOTING
SHARES		POWER
	8	
BENEFICIALLY		123,597 (See
OWNED BY		Items 3, 4 and
EACH REPORTING		5)

Edgar Filing: Sorrento Therapeutics, Inc. - Form SC 13D/A

PERSON WITH

- DISPOSITIVE
- 9 POWER

SOLE

-0-

10 SHARED DISPOSITIVE POWER

> 123,597 (See Items 3, 4 and 5)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING

11 PERSON

12

13

14

123,597 (See Items 3, 4 and 5) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN

- SHARES (see instructions) PERCENT OF CLASS
- REPRESENTED BY AMOUNT IN ROW 11

0.3% (See Item 5)* TYPE OF REPORTING PERSON

00

The calculation assumes that there are a total of 40,212,795 shares of Common Stock outstanding as of May 3, 2016, * as set forth in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the SEC on May 10, 2016.

CUSIP No. 83587F202 13DPage 6 of 15 Pages

NAMES OF REPORTING PERSONS

1

Infinity Q Diversified Alpha Fund CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

2 (see instructions)

(a)

(b)

3 SEC USE ONLY SOURCE OF FUNDS (see instructions)

4 ¹¹

5

WC (See Item 3) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) CITIZENSHIP OR PLACE OF

6 ORGANIZATION

Delaware

		VOTING
	7	POWER
		-0-
		SHARED
NUMBER OF		VOTING
SHARES		POWER
	8	
BENEFICIALLY		123,597 (See
OWNED BY		Items 3, 4 and
EACH REPORTING		5)
	9	

SOLE

-0- 10 SHARED DISPOSITIVE POWER 123,597 (See Items 3, 4 and 5) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11 PERSON 11 PERSON 123,597 (See Items 3, 4 and 5) CHECK BOX IF THE AGGREGATE AMOUNT IN 12 ROW (11) EXCLUDES CERTAIN SHARES (see instructions) PERCENT OF CLASS REPRESENTED BY 13 AMOUNT IN ROW 11	
Items 3, 4 and 5) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING 11 PERSON 11 PERSON 123,597 (See Items 3, 4 and 5) CHECK BOX IF THE AGGREGATE AMOUNT IN 12 ROW (11) EXCLUDES CERTAIN SHARES (see instructions) PERCENT OF CLASS REPRESENTED BY	
BENEFICIALLY OWNED BY EACH REPORTING PERSON 11 PERSON 123,597 (See Items 3, 4 and 5) CHECK BOX IF THE AGGREGATE AMOUNT IN 12 ROW (11) EXCLUDES CERTAIN SHARES (see instructions) PERCENT OF CLASS REPRESENTED BY	
BY EACH REPORTING PERSON11PERSON123,597 (See Items 3, 4 and 5) CHECK BOX IF THE AGGREGATE AMOUNT IN12ROW (11) EXCLUDES CERTAIN SHARES (see instructions) PERCENT OF CLASS REPRESENTED BY	
 PERSON 123,597 (See Items 3, 4 and 5) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) PERCENT OF CLASS REPRESENTED BY 	
5) CHECK BOX IF THE AGGREGATE AMOUNT IN 12 ROW (11) EXCLUDES CERTAIN SHARES (see instructions) PERCENT OF CLASS REPRESENTED BY	
0.3% (See Item 5)* TYPE OF REPORTING PERSON OO	

The calculation assumes that there are a total of 40,212,795 shares of Common Stock outstanding as of May 3, 2016, *as set forth in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the SEC on May 10, 2016.

CUSIP No. 83587F202 13DPage 7 of 15 Pages

NAMES OF REPORTING PERSONS

1

Bonderman Family Limited Partnership CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

2 (see instructions)

(a)

(b)

3 SEC USE ONLY SOURCE OF FUNDS (see

4 instructions)

Texas

WC (See Item 3) CHECK IF DISCLOSURE OF LEGAL

5 PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) CITIZENSHIP OR PLACE OF ORGANIZATION

6

		SOLE VOTING
	7	POWER
		0
		-0-
		SHARED
NUMBER OF		VOTING
SHARES		POWER
	8	
BENEFICIALLY		2,799,790 (See
OWNED BY		Items 3, 4 and
EACH REPORTING		5)
	9	SOLE
PERSON WITH		DISPOSITIVE

Edgar Filing: Sorrento Therapeutics, Inc. - Form SC 13D/A

POWER

-0-10 SHARED DISPOSITIVE POWER 2,799,790 (See Items 3, 4 and 5) AGGREGATE AMOUNT **BENEFICIALLY OWNED** BY EACH REPORTING PERSON 2,799,790 (See Items 3, 4 and 5) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) **EXCLUDES** CERTAIN SHARES (see instructions) PERCENT OF CLASS **REPRESENTED BY** AMOUNT IN ROW 11 7.0% (See Item 5)* **TYPE OF REPORTING**

11

12

13

14

PN

PERSON

The calculation assumes that there are a total of 40,212,795 shares of Common Stock outstanding as of May 3, 2016, *as set forth in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the SEC on May 10, 2016.

CUSIP No. 83587F202 13D Page 8 of 15 Pages

NAMES OF REPORTING PERSONS

1

Leonard A. Potter CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

2

(see instructions)

(a)

(b) 3 SEC USE ONLY SOURCE OF FUNDS (see instructions)

4

OO (See Item 3) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED

PURSUANT TO ITEM 2(d) or 2(e) CITIZENSHIP OR PLACE OF ORGANIZATION

> SOLE VOTING

6

5

United States

	7	POWER
		-0- SHARED
NUMBER OF SHARES	_	VOTING POWER
BENEFICIALLY	8	2,799,790 (See
OWNED BY EACH REPORTING		Items 3, 4 and 5)
PERSON WITH	9	SOLE DISPOSITIVE POWER

	Edgar Filing: Sorrento Therapeutics, Inc Form SC 13D/A
	-0- 10 SHARED
	DISPOSITIVE POWER
	2,799,790 (See Items 3, 4 and
	5)
	AGGREGATE AMOUNT
	BENEFICIALLY OWNED
	BY EACH REPORTING
11	PERSON
	2,799,790 (See Items 3, 4 and
	5)
	CHECK BOX IF
	THE AGGREGATE
	AGOREGATE AMOUNT IN
12	ROW (11)
12	EXCLUDES
	CERTAIN
	SHARES (see
	instructions)
	PERCENT OF CLASS
	REPRESENTED BY
13	AMOUNT IN ROW 11
	7.0% (See Item 5)*
	TYPE OF REPORTING
14	PERSON
	IN

The calculation assumes that there are a total of 40,212,795 shares of Common Stock outstanding as of May 3, 2016, *as set forth in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the SEC on May 10, 2016.

CUSIP No. 83587F202 13DPage 9 of 15 Pages

NAMES OF REPORTING PERSONS

1

James Velissaris CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

2 (see instructions)

(a)

(b)

3 SEC USE ONLY SOURCE OF FUNDS (see instructions)

4

OO (See Item 3) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)CITIZENSHIP OR PLACE OF

6

EACH REPORTING

5

United States

ORGANIZATION

		SOLE
		VOTING
	7	POWER
		-0-
		SHARED
NUMBER OF		VOTING
SHARES		POWER
	8	
BENEFICIALLY		123,597 (See
OWNED BY		Items 3, 4 and

5)

PERSON WI	TH	SOLE DISPOSITIVE POWER
	10	-0- SHARED DISPOSITIVE POWER
		123,597 (See Items 3, 4 and 5)
		TE AMOUNT
		ALLY OWNED
		REPORTING
11	PERSON	
	, ,	e Items 3, 4 and
	5)	V IF
	CHECK BO THE	X IF
	AGGREGA	TF
	AMOUNT I	
12	ROW (11)	
	EXCLUDES	5
	CERTAIN	
	SHARES (se	
	PERCENT (
10	REPRESEN	
13	AMOUNT I	N ROW II
	0.3% (See It	em 5)*
	TYPE OF R	
1.4	PERSON	
14		
	IN	

The calculation assumes that there are a total of 40,212,795 shares of Common Stock outstanding as of May 3, 2016, *as set forth in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the SEC on May 10, 2016.

This Amendment No. 3 (the <u>"Amendmen</u>t") amends and supplements the Schedule 13D filed on April 18, 2016, as amended and supplemented by Amendment No. 1 filed on April 26, 2016 and Amendment No. 2 filed on May 6, 2016 (as so amended, the <u>"Original Schedule 13D</u>" and, as further amended and supplemented by this Amendment, the <u>"Schedule 13D</u>") by Wildcat Capital Management, LLC, Wildcat – Liquid Alpha, LLC, Infinity Q Capital Management, LLC, Infinity Q Management Equity, LLC, Infinity Q Diversified Alpha Fund, Bonderman Family Limited Partnership, Leonard A. Potter and James Velissaris with respect to the Common Stock of the Issuer. Capitalized terms used in this Amendment and not otherwise defined shall have the same meanings ascribed to them in the Original Schedule 13D.

Item 4. Purpose of Transaction

This Amendment amends and supplements Item 4 of the Original Schedule 13D by inserting the following after the fifth paragraph:

"On May 10, 2016, WLA and BFLP submitted a letter (the "May 10 Letter") to the Board reiterating their concerns and demands set forth in the May 5 Letter, including (i) termination of the Transactions, (ii) termination of Dr. Ji as the CEO and (iii) appointment of three directors to be nominated by WLA and BFLP to lead the Special Committee. The May 10 Letter highlighted WLA's and BFLP's concerns regarding the Issuer's press release of May 9, 2016 (the "May 9 Press Release") announcing that the Issuer had previously engaged financial advisors to assist the Issuer in exploring and evaluating strategic alternatives although such engagement was not previously disclosed. The May 10 Letter further provided that the May 9 Press Release failed to address WLA's and BFLP's concerns set forth in the May 5 Letter and restated WLA's and BFLP's intent to pursue their available remedies, including, among other things, legal action on their own and/or the Issuer's behalf. A copy of the May 10 Letter is attached as Exhibit 5."

Item 5. Interest in Securities of the Issuer

This Amendment amends and restates the second, third and fourth paragraphs of Item 5 of the Original Schedule 13D in their entirety as set forth below:

"(a)–(b) The following disclosure assumes that there are a total of 40,212,795 shares of Common Stock outstanding as of May 3, 2016, which is based on information provided in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the SEC on May 10, 2016.

Pursuant to Rule 13d-3 of the Act, the Reporting Persons may be deemed to beneficially own, in the aggregate, 2,799,790 shares of Common Stock, which constitutes approximately 7.0% of the outstanding Common Stock.

(c) Except as set forth in Schedule II hereto, none of the Reporting Persons nor, to the best knowledge of the Reporting Persons, without independent verification, any person named in Item 2 hereof, has effected any transaction in the Common Stock during the past 60 days."

Item 7. Material to Be Filed as Exhibits

Edgar Filing: Sorrento Therapeutics, Inc. - Form SC 13D/A

This Amendment amends and restates Item 7 of the Original Schedule 13D in its entirety as set forth below:

1.Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Act.2.Demand for Inspection of Books and Records, dated April 11, 2016.3. Verified Complaint for Inspection of Books and Records filed in the Court of Chancery of the State of Delaware on April 25, 2016.

Letter to the Board of Directors of the Issuer, dated May 5, 2016.

Page 10 of 15 Pages

4.

5. Letter to the Board of Directors of the Issuer, dated May 10, 2016.

Page 11 of 15 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: May 11, 2016

Wildcat Capital Management, LLC

By: <u>/s/ Leonard A. Potter</u> Name: Leonard A. Potter Title: President

Wildcat - Liquid Alpha, LLC

By: <u>/s/ Clive Bode</u> Name: Clive Bode Title: President

Infinity Q Capital Management, LLC

By: <u>/s/ Leonard A. Potter</u> Name: Leonard A. Potter Title: Chief Executive Officer

Infinity Q Management Equity, LLC

By: <u>/s/ James Velissaris</u> Name: James Velissaris Title: Sole Manager

Infinity Q Diversified Alpha Fund

By: Infinity Q Capital Management, LLC

By: <u>/s/ Leonard A. Potter</u> Name: Leonard A. Potter Title: Chief Executive Officer Page 12 of 15 Pages

Bonderman Family Limited Partnership

By: <u>/s/ Clive Bode</u> Name: Clive Bode Title: President

Leonard A. Potter

By: /s/ Leonard A. Potter Name: Leonard A. Potter

James Velissaris

By: <u>/s/ James Velissaris</u> Name: James Velissaris

Page 13 of 15 Pages

Schedule II

Reporting Person	<u>Buy (B) / Sell (S</u>	S) Trade Date Type of Transaction	Quantity Price per Share
Bonderman Family Limited Partnership	В	05/06/2016 Open Market (NASDAQ)	74,537 \$5.575
Bonderman Family Limited Partnership	В	05/10/2016 Open Market (NASDAQ)	101,720 \$5.638

Page 14 of 15 Pages

INDEX TO EXHIBITS

Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Act.*

Demand for Inspection of Books and Records, dated April 11, 2016.**

4.

1.

2.

5.

Letter to the Board of Directors of the Issuer, dated May 5, 2016.****

Letter to the Board of Directors of the Issuer, dated May 10, 2016.

**Incorporated herein by reference to Demand for Inspection of Books and Records, dated April 11, 2016, which was previously filed with the SEC as Exhibit 2 to Schedule 13D filed by Wildcat Capital Management, LLC, Wildcat – Liquid Alpha, LLC, Infinity Q Capital Management, LLC, Infinity Q Management Equity, LLC, Infinity Q Diversified Alpha Fund, Bonderman Family Limited Partnership, Leonard A. Potter and James Velissaris, on April 18, 2016.

***Incorporated herein by reference to Verified Complaint for Inspection of Books and Records filed in the Court of Chancery of the State of Delaware on April 25, 2016, which was previously filed with the SEC as Exhibit 3 to Amendment No. 1 to Schedule 13D filed by Wildcat Capital Management, LLC, Wildcat – Liquid Alpha, LLC, Infinity Q Capital Management, LLC, Infinity Q Management Equity, LLC, Infinity Q Diversified Alpha Fund, Bonderman Family Limited Partnership, Leonard A. Potter and James Velissaris, on April 26, 2016.

****Incorporated herein by reference to Letter to the Board of Directors of the Issuer, dated May 5, 2016, which was previously filed with the SEC as Exhibit 4 to Amendment No. 2 to Schedule 13D filed by Wildcat Capital Management, LLC, Wildcat – Liquid Alpha, LLC, Infinity Q Capital Management, LLC, Infinity Q Management Equity, LLC, Infinity Q Diversified Alpha Fund, Bonderman Family Limited Partnership, Leonard A. Potter and James Velissaris, on May 6, 2016.

^{3.} Verified Complaint for Inspection of Books and Records filed in the Court of Chancery of the State of Delaware on April 25, 2016.***

^{*}Incorporated herein by reference to the Agreement of Joint Filing by and among Wildcat Capital Management, LLC, Wildcat – Liquid Alpha, LLC, Infinity Q Capital Management, LLC, Infinity Q Management Equity, LLC, Infinity Q Diversified Alpha Fund, Bonderman Family Limited Partnership, Leonard A. Potter and James Velissaris, dated as of April 18, 2016, which was previously filed with the SEC as Exhibit 1 to Schedule 13G filed by Wildcat Capital Management, LLC, Infinity Q Management, LLC, Wildcat – Liquid Alpha, LLC, Infinity Q Capital Management, LLC, Infinity Q Management Equity, LLC, Infinity Q Diversified Alpha Fund, Bonderman Family Limited Partnership, Leonard A. Potter and James Velissaris, on April 18, 2016.

Page 15 of 15 Pages